Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
University of Chicago
Summary
The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Inclusion Criteria Phase I * Patients must have a histologically confirmed malignancy that is to receive exclusively ICIs (no chemotherapy or RT in combination) per standard of care during the time in which lactulose will be administered. This includes, but is not limited to, melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI/MMRd cancer, cancers with high tumor mutational burden (\>=10 muts/mB), esophage…
Interventions
- DrugLactulose
Lactulose 10 g daily with standard-of-care Immune checkpoint inhibitors (ICIs).
Location
- University of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois